OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Update

OnKure Therapeutics, Inc. (NASDAQ:OKUR) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totaling 24,394 shares, a decrease of 53.1% from the December 15th total of 51,986 shares. Based on an average daily volume of 103,510 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the shares of the stock are sold short. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily volume of 103,510 shares, the days-to-cover ratio is presently 0.2 days.

OnKure Therapeutics Stock Performance

NASDAQ:OKUR traded up $0.05 during midday trading on Wednesday, reaching $3.19. 35,279 shares of the stock traded hands, compared to its average volume of 75,075. The stock has a market capitalization of $43.22 million, a P/E ratio of -0.67 and a beta of 0.47. The company has a fifty day moving average of $2.97 and a 200 day moving average of $2.75. OnKure Therapeutics has a 12 month low of $1.70 and a 12 month high of $6.87.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.11. On average, analysts predict that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

OKUR has been the subject of a number of recent research reports. Wall Street Zen upgraded OnKure Therapeutics to a “sell” rating in a research report on Saturday, November 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $32.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new stake in shares of OnKure Therapeutics in the 2nd quarter worth approximately $25,000. Bailard Inc. purchased a new stake in OnKure Therapeutics in the second quarter worth $34,000. Rangeley Capital LLC purchased a new stake in OnKure Therapeutics in the second quarter worth $71,000. GSA Capital Partners LLP boosted its holdings in OnKure Therapeutics by 172.1% in the third quarter. GSA Capital Partners LLP now owns 59,224 shares of the company’s stock valued at $163,000 after acquiring an additional 37,459 shares in the last quarter. Finally, Prosight Management LP increased its position in OnKure Therapeutics by 67.8% during the 3rd quarter. Prosight Management LP now owns 267,959 shares of the company’s stock valued at $737,000 after purchasing an additional 108,267 shares during the period. Institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.